309 results match your criteria Livedoid Vasculopathy


A novel use of intermittent low dose dabigatran for maintenance of remission in livedoid vasculopathy.

Dermatol Ther 2021 May 24:e14997. Epub 2021 May 24.

Department of Dermatology, Venereology & Leprology, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India.

View Article and Full-Text PDF

Cutaneous Manifestations in the Context of SARS-CoV-2 Infection (COVID-19).

Actas Dermosifiliogr 2020 Nov 15;111(9):734-742. Epub 2020 Oct 15.

Servicio de Dermatología, Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Barcelona, Spain.

The coronavirus 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has had enormous health, economic, and social consequences. The clinical spectrum of cutaneous manifestations observed in patients with COVID-19 is both heterogeneous and complex. To date, reports have identified 5 main categories: acral lesions, vesicular rashes, urticarial rashes, maculopapular rashes, and livedoid and necrotic lesions. Read More

View Article and Full-Text PDF
November 2020

A Case of Livedoid Vasculopathy Successfully Treated with Sulodexide.

Ann Dermatol 2020 Dec 11;32(6):508-511. Epub 2020 Nov 11.

Department of Dermatology, Hanyang University Guri Hospital, Guri, Korea.

We report a 29-year-old female with a one-month history of non-healing multiple erythematous to violaceous plaques with crusts over both legs and feet. Tender, scarring ulcers with surrounding erythema were present. The clinical manifestation, together with histopathologic findings of fibrinoid plugs within vascular lumens and walls, as well as red blood cell extravasation, led to diagnosis of livedoid vasculopathy. Read More

View Article and Full-Text PDF
December 2020

Cutaneous Vasculopathy in a COVID-19 Critically Ill Patient: A Histologic, Immunohistochemical, and Electron Microscopy Study.

Case Rep Crit Care 2021 3;2021:6644853. Epub 2021 Apr 3.

ICU, 1st Department of Respiratory Medicine, National and Kapodistrian University of Athens Medical School, "Sotiria" Hospital, Athens, Greece.

We describe a critically ill, SARS-CoV-2 positive patient with respiratory failure and thrombotic/livedoid skin lesions, appearing during the course of the disease. The biopsy of the lesions revealed an occlusive, pauci-inflammatory vasculopathy of the cutaneous small vessels characterized by complement and fibrinogen deposition on vascular walls, pointing to a thrombotic vasculopathy. Transmission electron microscopy of the affected skin failed to reveal any viral inclusions. Read More

View Article and Full-Text PDF

Cutaneous involvement by T-cell prolymphocytic leukemia presenting as livedoid vasculopathy.

J Cutan Pathol 2021 Jul 20;48(7):975-979. Epub 2021 Apr 20.

Department of Pathology, Duke University Medical Center, Durham, North Carolina, USA.

T-cell prolymphocytic leukemia (T-PLL) is a rare, aggressive neoplasm derived from post-thymic T-cells. Patients are typically middle aged with a slight male predominance who present with a high white blood cell count, hepatosplenomegaly, lymphadenopathy, and other symptoms typically associated with leukemia. Although cutaneous involvement has been reported in up to 30% of cases of T-PLL, to our knowledge, none have presented with a presentation resembling livedoid vasculopathy. Read More

View Article and Full-Text PDF

Intravenous Immunoglobulin Therapy in Livedoid Vasculopathy: Retrospective Observation of Clinical Outcome and Patient's Activity Level.

J Cutan Med Surg 2021 Mar 28:12034754211003525. Epub 2021 Mar 28.

9188 Department of Dermatology, Eberhard-Karls University, Tübingen, Germany.

Background: Livedoid vasculopathy (LV) is a rare disease characterized by livedo racemosa, atrophie blanche, ulcerations, and severe pain. Low molecular weight heparins and rivaroxaban can be used in LV-patients. In addition, intravenous immunoglobulins (IVIG) have been described as treatment-option. Read More

View Article and Full-Text PDF

Brachial plexopathy as a complication of COVID-19.

BMJ Case Rep 2021 Mar 25;14(3). Epub 2021 Mar 25.

Neurology, Weill Cornell Medicine, New York City, New York, USA.

COVID-19 affects a wide spectrum of organ systems. We report a 52-year-old man with hypertension and newly diagnosed diabetes mellitus who presented with hypoxic respiratory failure due to COVID-19 and developed severe brachial plexopathy. He was not treated with prone positioning respiratory therapy. Read More

View Article and Full-Text PDF

Livedoid vasculopathy and its association with genetic variants: A systematic review.

Int Wound J 2021 Mar 8. Epub 2021 Mar 8.

Department of Dermatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Livedoid vasculopathy (LV) is considered a disease of hypercoagulability. Association of LV with genetic variants is poorly characterised and large-scale genetic association studies have not been performed. The aim of the study was to systematically review variants in LV patients and to analyse the available clinical data. Read More

View Article and Full-Text PDF

Remission of long-standing livedoid vasculopathy using a whole foods plant-based diet with symptoms recurrent on re-challenge with standard Western diet.

BMJ Case Rep 2021 Feb 23;14(2). Epub 2021 Feb 23.

Hauora Tairawhiti, Gisborne, New Zealand.

A 63-year-old woman presented with ulcerations of both lower legs. Symptom onset was 2006. In 2013 she saw a dermatologist and a biopsy suggested livedoid vasculopathy. Read More

View Article and Full-Text PDF
February 2021

Recrudescence of livedoid vasculopathy induced by COVID-19.

Int J Dermatol 2021 May 2;60(5):e185-e187. Epub 2021 Feb 2.

Departamento de Dermatologia e Radioterapia, FMB-UNESP, Botucatu, Brazil.

View Article and Full-Text PDF

Livedoid vasculopathy in 75 Brazilian patients in a single-center institution: Clinical, histopathological and therapy evaluation.

Dermatol Ther 2021 03 7;34(2):e14810. Epub 2021 Feb 7.

Department of Pathology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.

This study presents a single center experience with livedoid vasculopathy (LV). A rare disease that can lead to severe quality of life impairment. Characterize clinical data of LV patients at the Dermatology Division at the University of São Paulo. Read More

View Article and Full-Text PDF

Livedoid vasculopathy: Clinical course and long-term outcome in Asian patients with a review of the literature.

Dermatol Ther 2021 01 29;34(1):e14569. Epub 2020 Nov 29.

Department of Dermatology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.

Livedoid vasculopathy (LV) is an uncommon, chronic, and recurrent thrombo-occlusive vascular disorder. Data specific to LV in Thai population remains scarce. This study aimed to evaluate the clinical course and treatment outcomes of LV in Thai patients, and to perform a literature review for studies that reported on anticoagulant treatment in LV. Read More

View Article and Full-Text PDF
January 2021

From dermatological conditions to COVID-19: Reasoning for anticoagulation, suppression of inflammation, and hyperbaric oxygen therapy.

Dermatol Ther 2021 Jan 30;34(1):e14565. Epub 2020 Nov 30.

Department of Pathology and Forensic Medicine, Faculdade de Medicina de Ribeirão Preto da USP, São Paulo, Brazil.

COVID-19 generates a complex systemic inflammatory response that can lead to death due to wide macrophage activation, endothelial damage, and coagulation in critically ill patients. SARS-CoV-2-induced lung injury due to inflammatory mediated thrombosis could be similar to the livedoid vasculopathy in the skin, supporting a translational comparison of these clinical settings. In this article, we discuss anticoagulation, suppression of inflammatory response, and hyperbaric oxygen therapy in the context of severe COVID-19 and livedoid vasculopathy. Read More

View Article and Full-Text PDF
January 2021

[Non-healing wounds].

Ned Tijdschr Geneeskd 2020 10 22;164. Epub 2020 Oct 22.

Erasmus Medisch Centrum, afd. Dermatologie, Rotterdam.

The incidence of non-healing wounds is increasing. Identification of the underlying cause of a wound is of essential importance for adequate treatment. In this article, we present three female patients aged 50, 65 and 85 years with respectively pyoderma gangraenosum, livedoid vasculopathy and Martorell hypertensive ischaemic leg ulcer. Read More

View Article and Full-Text PDF
October 2020

Refractory ulcerations associated with livedoid vasculopathy successfully treated with tofacitinib.

Dermatol Ther 2020 11 16;33(6):e14470. Epub 2020 Nov 16.

The Department of Rheumatology, the fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Shenzhen, China.

View Article and Full-Text PDF
November 2020

Clinical and Histopathologic Characteristics of the Main Causes of Vascular Occusion - Part II: Coagulation Disorders, Emboli, and Other.

Actas Dermosifiliogr (Engl Ed) 2021 Feb 16;112(2):103-117. Epub 2020 Oct 16.

Servicio de Anatomía Patológica, Hospital Universitario de Cruces, Barakaldo, Vizcaya, España.

Vascular occlusion has multiple, diverse clinical manifestations, some of which can have grave consequences for patients. It also has a wide variety of causes, including thrombi, which we recently addressed in partI of this review. In this second part, we look at additional causes of vascular occlusion. Read More

View Article and Full-Text PDF
February 2021

Intravenous Immunoglobulins in a Series of 32 Rare and Recalcitrant Immune Dermatoses.

Acta Derm Venereol 2020 Oct 21;100(17):adv00298. Epub 2020 Oct 21.

Division of Allergy and Immunology, Charité - Universitätsmedizin Berlin, DE-10117 Berlin, Germany.

Intravenous immunoglobulins are an effective and well-tolerated treatment option for immune dermatological diseases. However, they are primarily used to treat diseases with a severe course and are mostly used off-label. Therefore, it is important to document case series on the use of intravenous immunoglobulins in rare immune dermatological diseases. Read More

View Article and Full-Text PDF
October 2020

Plasminogen activator inhibitor-1: a potential etiological role in livedoid vasculopathy.

Int Wound J 2020 Dec 11;17(6):1902-1908. Epub 2020 Oct 11.

Department of Dermatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Livedoid vasculopathy (LV) is a chronic, recurrent skin disorder with unknown aetiology and pathogenesis that seriously affects the quality of life of people who suffer from it. Plasminogen activator inhibitor (PAI)-1 is a primary inhibitory component of the endogenous fibrinolytic system in blood coagulation. PAI-1 also plays a role in many other physiological processes and activities, including thrombosis, fibrosis, wound healing, angiogenesis, inflammation, cell migration, and adhesion. Read More

View Article and Full-Text PDF
December 2020

[Diagnosis and treatment of vasculitic ulcerations].

Hautarzt 2020 Nov;71(11):870-879

Klinik fürHautkrankheiten, Universitätsklinikum Münster, Von-Esmarch-Str. 58, 48149, Münster, Deutschland.

Vasculitis is a rare cause of skin ulceration. Depending on the size of the affected vessel, the patient's comorbidities and the pathophysiology present, different clinical morphologies can be seen, which can often give preliminary indications of the type of underlying vasculitis. There may be systemic or cutaneous manifestations; thus, a targeted diagnostic workup should be initiated at an early stage. Read More

View Article and Full-Text PDF
November 2020

Direct immunofluorescence findings in livedoid vasculopathy: a 10-year study and literature review.

Clin Exp Dermatol 2021 Apr 17;46(3):525-531. Epub 2020 Oct 17.

Department of Dermatology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.

Background: Direct immunofluorescence (DIF) findings in patients with livedoid vasculopathy (LV) may have benefits for disease differentiation when clinical presentations and/or histopathological findings are inconclusive.

Aim: To investigate DIF findings in patients with a clinical and histopathological diagnosis of LV.

Methods: DIF findings of 62 patients with LV were analysed, and the published literature in the PubMed database was also reviewed and summarized. Read More

View Article and Full-Text PDF

Primary livedoid vasculopathy associated with mononeuritis multiplex.

Dermatol Online J 2020 Jul 15;26(7). Epub 2020 Jul 15.

Department of Dermatology, University of Massachusetts Medical School, Worcester, MA Department of Pediatrics, University of Massachusetts Medical School, Worcester, MA.

A 40-year-old woman presented with painful ulcerations on the bilateral lower extremities. A biopsy confirmed the diagnosis of livedoid vasculopathy (LV). She was treated initially with aspirin and pentoxifylline, and with the addition of dipyridamole she has had no recurrence of her ulcerations to date. Read More

View Article and Full-Text PDF

Cutaneous Manifestations in the Context of SARS-CoV-2 Infection (COVID-19).

Actas Dermosifiliogr (Engl Ed) 2020 Nov 31;111(9):734-742. Epub 2020 Aug 31.

Servicio de Dermatología, Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Barcelona, España.

The coronavirus 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus2 (SARS-CoV-2), has had enormous health, economic, and social consequences. The clinical spectrum of cutaneous manifestations observed in patients with COVID-19 is both heterogeneous and complex. To date, reports have identified 5main categories: acral lesions, vesicular rashes, urticarial rashes, maculopapular rashes, and livedoid and necrotic lesions. Read More

View Article and Full-Text PDF
November 2020

Clinical and dermoscopic features of livedoid vasculopathy.

Chin Med J (Engl) 2020 Sep;133(17):2137-2138

Department of Dermatology and Venerology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, China.

View Article and Full-Text PDF
September 2020

Reticular skin eruption as the initial sign of coronavirus disease 2019 infection.

JAAD Case Rep 2020 Aug 24;6(8):790-792. Epub 2020 Jun 24.

Department of Dermatology, Columbia University Irving Medical Center, New York, New York.

View Article and Full-Text PDF

Livedoid and Purpuric Skin Eruptions Associated With Coagulopathy in Severe COVID-19.

JAMA Dermatol 2020 09;156(9):1-3

Department of Dermatology, NewYork-Presbyterian/Weill Cornell Medical College, New York.

View Article and Full-Text PDF
September 2020

Livedoid vasculopathy: A challenging disease to diagnose.

J Paediatr Child Health 2021 May 3;57(5):721-722. Epub 2020 Jul 3.

Department of Pediatric Rheumatology, University of Health Sciences, Ankara City Hospital, Ankara, Turkey.

View Article and Full-Text PDF

Methylene tetrahydrofolate reductase C677T polymorphism in Korean livedoid vasculopathy patients.

Authors:
Ji Su Lee Soyun Cho

J Am Acad Dermatol 2021 Apr 27;84(4):1068-1069. Epub 2020 Jun 27.

Department of Dermatology, Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Seoul, Korea; Department of Dermatology, Seoul National University College of Medicine, Seoul, Korea. Electronic address:

View Article and Full-Text PDF

Cutaneous manifestations of SARS-CoV-2 infection: a clinical update.

J Eur Acad Dermatol Venereol 2020 Nov 20;34(11):2499-2504. Epub 2020 Jul 20.

Division of Dermatology, San Bortolo Hospital, Vicenza, Italy.

On 11 March 2020, the World Health Organization (WHO) has declared the novel coronavirus disease (COVID-19) a global pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 virus). A consistent number of case reports and clinical series have been already published describing a complex spectrum of skin manifestations associated with the SARS-CoV-2 infection. We carried out a review of the English-language literature up to 20 May 2020, reporting original cases or case series of the cutaneous manifestations of SARS-CoV-2 virus infection. Read More

View Article and Full-Text PDF
November 2020

Unraveling the mystery of Covid-19 cytokine storm: From skin to organ systems.

Dermatol Ther 2020 11 7;33(6):e13859. Epub 2020 Jul 7.

Department of Pulmonary Medicine, Post Graduate Institute of Medical Education and Research, Chandigarh, India.

COVID-19 is a global pandemic that emerged from Wuhan, China. Besides pneumonia and acute respiratory distress syndrome, the disease leads to multisystem involvement in the form of myocarditis, arrhythmias, cardiac arrest, gastrointestinal symptoms, hypoxemic brain injury, acute liver, and renal function impairment. There are also reports of cutaneous lesions in form of urticarial and maculopapular rashes, chilblain like fingers and toes (covid feet), livedoid vasculopathy, and chicken-pox like or varicelliform vesicles. Read More

View Article and Full-Text PDF
November 2020